Clinical Trials Logo

Castration-Resistant Prostate Cancer clinical trials

View clinical trials related to Castration-Resistant Prostate Cancer.

Filter by:

NCT ID: NCT01981109 Terminated - Clinical trials for Castration-Resistant Prostate Cancer

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

PREDICT
Start date: January 2012
Phase:
Study type: Observational

The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.

NCT ID: NCT01703065 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Start date: June 18, 2013
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01522443 Terminated - Prostate Cancer Clinical Trials

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

COMET-2
Start date: March 2012
Phase: Phase 3
Study type: Interventional

Bone metastases and associated pain are a major cause of morbidity and mortality in castration-resistant prostate cancer (CRPC). Most approved therapies have shown some ability to reduce soft tissue lesions but none meaningfully impacts bone metastases (as demonstrated by lack of resolution of lesions on bone scan with these agents) or the pain associated with these metastases. This study will evaluate the effect of cabozantinib versus mitoxantrone plus prednisone on pain response and bone scan response in men with CRPC.